Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: current advancements and future perspectives
Name:
Revolutionizing anti....pdf
Size:
2.616Mb
Format:
PDF
Description:
Found with Open Access Button
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.Issue Date
2024
Metadata
Show full item recordAbstract
Biliary tract cancers (BTCs) encompass a heterogeneous group of rare tumors, including intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), gallbladder cancer (GBC) and ampullary cancer (AC). The present first-line palliative treatment regimen comprises gemcitabine and cisplatin in combination with immunotherapy based on two randomized controlled studies. Despite the thorough investigation of these palliative treatments, long-term survival remains low. Moving beyond conventional chemotherapies and immunotherapies, the realm of precision medicine has demonstrated remarkable efficacy in malignancies such as breast and gastric cancers, characterized by notable HER2 overexpression rates. In the context of biliary tract cancer, significant HER2 alterations are observed, particularly within eCCA and GBC, heightening the interest in precision medicine. Various anti-HER2 therapies, including trastuzumab, pertuzumab, trastuzumab-deruxtecan, zanidatamab and neratinib, have undergone investigation. The objective of this review is to summarize the current evidence and outline future directions of targeted HER2 treatment therapy in patients with biliary tract tumors, specially extrahepatic cholangiocarcinoma and gallbladder cancer.Citation
Haaft BHT, Pedregal M, Prato J, Klümpen HJ, Moreno V, Lamarca A. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives. European journal of cancer (Oxford, England : 1990). 2024 Mar;199:113564. PubMed PMID: 38266541. Epub 2024/01/25.Journal
European Journal of CancerDOI
10.1016/j.ejca.2024.113564PubMed ID
38266541Additional Links
https://dx.doi.org/10.1016/j.ejca.2024.113564Type
ReviewLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2024.113564
Scopus Count
Collections
Related articles
- The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
- Authors: Kirimlioğlu H, Türkmen I, Başsüllü N, Dirican A, Karadağ N, Kirimlioğlu V
- Issue date: 2009 Mar
- The epidemiological trends of biliary tract cancers in the United States of America.
- Authors: Jiang Y, Jiang L, Li F, Li Q, Yuan S, Huang S, Fu Y, Yan X, Chen J, Li H, Li S, Liu J
- Issue date: 2022 Dec 29
- Time to move to targeted drugs in biliary tract cancer?
- Authors: Louvet C, Tournigand C
- Issue date: 2010
- Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
- Authors: Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, Kim MH, Park S, Kang B, Hong M, Kim JW, Park HS, Kang MJ, Park YN, Choi HJ
- Issue date: 2023 Jan
- Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma.
- Authors: Wheless M, Agarwal R, Goff L, Lockney N, Padmanabhan C, Heumann T
- Issue date: 2024 Jan